Breaking News Instant updates and real-time market news.

IOVA

Iovance Biotherapeutics

$23.63

2.97 (14.38%)

20:17
11/10/19
11/10
20:17
11/10/19
20:17

Piper Jaffray reiterates Overweight on Iovance after SITC update

Piper Jaffray analyst Joseph Catanzaro reiterated an Overweight rating and $30 price target on Iovance following the company's update for cohort 2 of melanoma's lifileucel study at SITC. The analyst said that even a worst case scenario on the data "points to an eventual very favorable mDOR for cohort 2." Catanzaro reiterated that he believes "this has implications around commercial adoption and peak penetration if replicated in cohort 4," which is projected to complete enrollment in the Q1 of 2020, with a regulatory filing in late 2020.

IOVA Iovance Biotherapeutics
$23.63

2.97 (14.38%)

07/02/19
HCWC
07/02/19
NO CHANGE
Target $32
HCWC
Buy
H.C. Wainwright reiterates Buy, $32 price target on Iovance
H.C. Wainwright analyst Joseph Pantginis reiterates a Buy rating on Iovance Biotherapeutics with a $32 price target after the company disclosed updates regarding the regulatory path for LN-145 in cervical cancer. With the possibility for innovaTIL-04 study to be registrational, the company is "reasonably" planning a path for a Biologics License Application submission in the second half of 2020, Pantginis tells investors in a research note. The analyst believes LN-145 "deserves the attention it is receiving." While the primary focus remains on Iovance's initial path to market with lifileucel in melanoma, LN-145 is a "potential rapid follower to commercialization," says Pantginis.
08/26/19
JEFF
08/26/19
NO CHANGE
Target $33
JEFF
Buy
Iovance pullback brings buying opportunity, says Jefferies
Jefferies analyst Biren Amin views the recent pullback in shares of Iovance Biotherapeutics as a buying opportunity into the end of 2019. After meeting with management, the analyst believes the melanoma and cervical pivotal cohorts appear to be enrolling patients with Iovance on track toward finishing patient enrollment in the melanoma study in Q1 of 2020. He thinks there is some likelihood of data at SITC in November and keeps a Buy rating on the shares with a $33 price target.
09/30/19
STFL
09/30/19
INITIATION
Target $27
STFL
Buy
Iovance Biotherapeutics initiated with a Buy at Stifel
Stifel analyst Benjamin Burnett started Iovance Biotherapeutics with a Buy rating and $27 price target. The analyst says his physician checks corroborate the view that the company's lifileucel and LN-145 data are "very good" and supportive of being the best therapeutic option in their respective advanced settings. He believes the market opportunity for an autologous tumor-infiltrating lymphocyte product in the advanced melanoma/cervical cancer setting can reach $2B-plus sales at peak.
11/08/19
PIPR
11/08/19
NO CHANGE
Target $30
PIPR
Overweight
Iovance data suggests durable responses in melanoma study, says Piper Jaffray
After Iovance Biotherapeutics presented new data from Cohort 2 of the ongoing Phase 2 lifileucel metastatic melanoma study, Piper Jaffray analyst Joseph Catanzaro said the fact that median duration of response, or DOR, has not yet been reached at a median follow-up of 12.8 months per investigator assessment suggests durable responses are being seen with the drug. The analyst, who said he expects the data to continue to "mature favorably," sees ultimate implications on commercial adoption and peak penetration, he noted. He keeps an Overweight rating on Iovance shares.

TODAY'S FREE FLY STORIES

02:55
11/21/19
11/21
02:55
11/21/19
02:55
General news
FX Update: The yen edged out fresh lows before paring losses »

FX Update: The yen edged…

02:05
11/21/19
11/21
02:05
11/21/19
02:05
General news
U.S. Philly Fed manufacturing index preview: »

U.S. Philly Fed…

02:05
11/21/19
11/21
02:05
11/21/19
02:05
General news
U.S. initial jobless claims preview: »

U.S. initial jobless…

02:05
11/21/19
11/21
02:05
11/21/19
02:05
General news
U.S. Philly Fed index rose X points to X8 in November »

U.S. Philly Fed index…

02:00
11/21/19
11/21
02:00
11/21/19
02:00
General news
Asian Market Update: »

Asian Market Update: JGBs…

M

Macy's

$15.02

-0.01 (-0.07%)

, SFL

Ship Finance

$14.45

0.03 (0.21%)

20:25
11/20/19
11/20
20:25
11/20/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

M

Macy's

$15.02

-0.01 (-0.07%)

SFL

Ship Finance

$14.45

0.03 (0.21%)

BJ

BJ's Wholesale

$26.03

-0.29 (-1.10%)

PLAN

Anaplan

$49.16

0.32 (0.66%)

BERY

Berry Global

$41.90

-0.09 (-0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

PFGC

Performance Food Group

$44.66

-0.13 (-0.29%)

20:19
11/20/19
11/20
20:19
11/20/19
20:19
Syndicate
Performance Food Group 10.12M share Secondary priced at $44.25 »

Wells Fargo and Credit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

ALPMY

Astellas Pharma

$0.00

(0.00%)

20:02
11/20/19
11/20
20:02
11/20/19
20:02
Hot Stocks
Astellas Pharma, Welldoc enter into Digital Therapeutics alliance »

Astellas Pharma and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

PYPL

PayPal

$104.09

-0.85 (-0.81%)

19:52
11/20/19
11/20
19:52
11/20/19
19:52
Recommendations
PayPal analyst commentary at Baird »

PayPal's Honey…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

  • 10

    Dec

SQM

SQM

$23.41

-0.35 (-1.47%)

19:42
11/20/19
11/20
19:42
11/20/19
19:42
Earnings
SQM reports Q3 EPS 23c, consensus 26c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

TNAV

TeleNav

$4.92

0.07 (1.44%)

19:37
11/20/19
11/20
19:37
11/20/19
19:37
Hot Stocks
TeleNav CEO buys 150K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

CRSP

Crispr Therapeutics

$67.31

-1.15 (-1.68%)

19:29
11/20/19
11/20
19:29
11/20/19
19:29
Syndicate
Breaking Syndicate news story on Crispr Therapeutics »

Crispr Therapeutics 4.25M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 21

    Nov

PFGC

Performance Food Group

$44.66

-0.13 (-0.29%)

19:26
11/20/19
11/20
19:26
11/20/19
19:26
Syndicate
Performance Food Group upsized 10.1M share offering said to price at $44.25 »

Report from Bloomberg. …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

INVH

Invitation Homes

$30.05

0.13 (0.43%)

19:10
11/20/19
11/20
19:10
11/20/19
19:10
Periodicals
Breaking Periodicals news story on Invitation Homes »

Invitation Homes stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

KRTX

Karuna Therapeutics

$108.42

-15.58 (-12.56%)

19:03
11/20/19
11/20
19:03
11/20/19
19:03
Syndicate
Karuna Therapeutics 2.6M share Secondary priced at $96.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

GOOG

Alphabet

$1,302.26

-12.45 (-0.95%)

, GOOGL

Alphabet Class A

$1,301.34

-11.25 (-0.86%)

18:58
11/20/19
11/20
18:58
11/20/19
18:58
Hot Stocks
Google to limit election ads audience targeting, will prohibit 'deep fakes' »

Alphabet's Google…

GOOG

Alphabet

$1,302.26

-12.45 (-0.95%)

GOOGL

Alphabet Class A

$1,301.34

-11.25 (-0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAN

Canaan

$0.00

(0.00%)

18:56
11/20/19
11/20
18:56
11/20/19
18:56
Syndicate
Canaan 10M share IPO priced at $9.00 »

The deal priced at low…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

NUAN

Nuance

$16.60

0.11 (0.67%)

, CPRT

Copart

$84.69

-1.64 (-1.90%)

18:51
11/20/19
11/20
18:51
11/20/19
18:51
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Nuance…

NUAN

Nuance

$16.60

0.11 (0.67%)

CPRT

Copart

$84.69

-1.64 (-1.90%)

LB

L Brands

$16.00

-1.19 (-6.92%)

JACK

Jack in the Box

$84.89

-0.08 (-0.09%)

SONO

Sonos

$13.87

-0.635 (-4.38%)

NTGN

Neon Therapeutics

$1.44

-0.04 (-2.70%)

TIF

Tiffany

$123.32

-0.16 (-0.13%)

UBER

Uber

$28.02

0.99 (3.66%)

LZB

La-Z-Boy

$36.23

-0.265 (-0.73%)

CUB

Cubic

$73.63

0.8 (1.10%)

NTES

NetEase

$287.68

-1.09 (-0.38%)

OPTN

Optinose

$11.42

0.84 (7.94%)

MTEM

Molecular Templates

$8.28

0.19 (2.35%)

PYPL

PayPal

$104.09

-0.85 (-0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 04

    Dec

  • 05

    Dec

  • 05

    Dec

  • 06

    Dec

  • 10

    Dec

  • 10

    Dec

  • 21

    Nov

  • 21

    Nov

WNC

Wabash

$15.05

-0.2 (-1.31%)

18:48
11/20/19
11/20
18:48
11/20/19
18:48
Initiation
Wabash initiated at Raymond James »

Wabash initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALSN

Allison Transmission

$45.51

-0.56 (-1.22%)

18:47
11/20/19
11/20
18:47
11/20/19
18:47
Initiation
Allison Transmission initiated at Raymond James »

Allison Transmission…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NAV

Navistar

$30.97

-0.97 (-3.04%)

18:47
11/20/19
11/20
18:47
11/20/19
18:47
Initiation
Navistar initiated at Raymond James »

Navistar initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCAR

Paccar

$78.85

-0.59 (-0.74%)

18:47
11/20/19
11/20
18:47
11/20/19
18:47
Initiation
Paccar initiated at Raymond James »

Paccar initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMI

Cummins

$180.59

-2.36 (-1.29%)

18:46
11/20/19
11/20
18:46
11/20/19
18:46
Initiation
Cummins initiated at Raymond James »

Cummins initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

VMC

Vulcan Materials

$140.72

-0.485 (-0.34%)

18:45
11/20/19
11/20
18:45
11/20/19
18:45
Initiation
Vulcan Materials initiated at Deutsche Bank »

Vulcan Materials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SUM

Summit Materials

$24.18

0.3 (1.26%)

18:45
11/20/19
11/20
18:45
11/20/19
18:45
Initiation
Summit Materials initiated at Deutsche Bank »

Summit Materials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.